S
IBRX icon

SignatureFD’s ImmunityBio IBRX Stock Holding History

SignatureFD’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,000
Closed -$2.46K – 3468
2025
Q3 		$2.46K Sell
1,000
-52
-5% -$134 ﹤0.01% 2893
2025
Q2 		$2.78K Buy
1,052
+770
+273% +$2.07K ﹤0.01% 2783
2025
Q1 		$849 Buy
+282
New +$855 ﹤0.01% 3072
2022
Q4 		– Sell
-3,845
Closed -$19K – 3339
2022
Q3 		$19K Hold
3,845
– – ﹤0.01% 1757
2022
Q2 		$14K Hold
3,845
– – ﹤0.01% 1948
2022
Q1 		$22K Hold
3,845
– – ﹤0.01% 1792
2021
Q4 		$23K Buy
+3,845
New +$28.9K ﹤0.01% 1726

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SignatureFD's IBRX Position: Q4 2025 in Review

SignatureFD sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 1,000 shares — an estimated $2.46K sold.

SignatureFD first reported a position in IBRX in Q4 2021 and held it in 7 quarters. The position peaked at $23K in Q4 2021. 278 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

  • SignatureFD reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
  • SignatureFD sold 1,000 ImmunityBio shares in Q4 2025, an estimated $2.46K.
  • SignatureFD first reported a position in ImmunityBio in Q4 2021 and held it in 7 quarters.
  • SignatureFD's ImmunityBio position peaked at $23K in Q4 2021.
  • 278 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on SignatureFD's 13F filing for Q4 2025, filed 20 Jan 2026.